Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB
· Real-Time Price · USD
5.05
0.54 (11.97%)
At close: Jun 16, 2025, 3:59 PM
4.99
-1.19%
After-hours: Jun 16, 2025, 07:50 PM EDT
11.97% (1D)
| Bid | 4.57 |
| Market Cap | 391.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -139.68M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -1.6 |
| Forward PE | -2.14 |
| Analyst | Buy |
| Ask | 5.3 |
| Volume | 2,001,490 |
| Avg. Volume (20D) | 1,541,069 |
| Open | 4.35 |
| Previous Close | 4.51 |
| Day's Range | 4.35 - 5.29 |
| 52-Week Range | 2.41 - 10.37 |
| Beta | 2.22 |
About SLDB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SLDB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SLDB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+6.82%
Solid Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
-20.33%
Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.
2 months ago · seekingalpha.com
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy SpaceSolid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly im...
